Anne Wojcicki Secures Control of 23andMe Through Nonprofit Sale

A bankruptcy court has greenlit the sale of genetic testing company 23andMe to a nonprofit organization headed by its co-founder, Anne Wojcicki. The move effectively hands control of the struggling company back to its original leader, signaling a potential fresh start—or at least a controlled transition—for the once-high-flying DNA-testing pioneer.

Editor’s Note: This isn’t just another corporate shuffle—23andMe was a household name in consumer genetics, but privacy concerns, financial woes, and stiff competition left it in rough shape. Wojcicki’s return via a nonprofit structure raises big questions: Will this save the company, or is it more about managing its decline? Either way, it’s a pivotal moment for the future of personal DNA testing and how our genetic data is handled.

A bankruptcy court just greenlit the sale of genetic testing company 23andMe to a nonprofit organization headed by its co-founder, Anne Wojcicki. This means the struggling company—once a household name in DNA ancestry kits—will essentially get a second life under Wojcicki’s leadership, but with a nonprofit structure.

Editor’s Note: This isn’t just another corporate shuffle—it’s a rare case of a high-profile tech company pivoting to nonprofit status under its original leader. For customers, it raises questions: Will 23andMe’s services change? What happens to user data? And for the industry, it’s a sign of how tough the direct-to-consumer genetics market has become, even for pioneers.

Anne Wojcicki, the co-founder of 23andMe, has outmaneuvered Regeneron in a bidding war for the DNA-testing company. Her nonprofit stepped in with a higher offer, securing control and keeping the future of 23andMe in her hands—at least for now.

Editor’s Note: This isn’t just a business deal—it’s a power play that could shape the future of consumer genetics. Wojcicki’s move suggests she’s not ready to let go of the company she helped build, even as it struggles financially. For customers and investors, it raises questions: Will this keep 23andMe independent, or is it just a temporary fix? Either way, the drama isn’t over.